The Genentech target option is a significant platform validation that may drive sentiment, but the revenue miss and elevated cash burn are real headwinds. Watch for the REC-4881 FDA regulatory update and additional Phase 2 data at CGA-IGC in November 2026, which could be the next major catalyst. The lowered cash burn guidance provides a clearer runway, but the company remains pre-revenue from product sales.
Price Chart
Executive Summary
Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 consensus), a miss on both top and bottom lines. The headline financials are weak, but the stock is likely to move on the operational catalyst: Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a novel target into early discovery—a key platform validation. The company also lowered 2026 cash operating expense guidance to $375M (from $390M), extending runway into early 2028 without additional financing.
Key Financial Metrics
Key Facts
- Revenue of $7.7M missed consensus of $12.0M and declined 60% YoY from $19.2M.
- GAAP EPS of -$0.25 missed consensus of -$0.23.
- Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a previously unexplored target into a joint early discovery program.
- REC-7735 (PI3K H1047R inhibitor) IND cleared; Phase 1/2 ZINNIA trial to start in 2H26.
- 2026 cash operating expense guidance lowered to $375M (from $390M), extending cash runway into early 2028.
- Cash, cash equivalents and restricted cash were $556.8M as of June 30, 2026.
Financial Impact
Revenue miss of ~36% vs consensus ($7.7M actual vs $12.0M est); EPS miss of ~8.7% (-$0.25 vs -$0.23). Net loss improved to -$131.0M from -$171.9M YoY, but cash burn increased to -$105.9M in operating cash flow vs -$76.4M in Q2 2025.
Risk Factors
- Revenue is entirely collaboration-dependent and declined 60% YoY as prior partner projects completed.
- Cash burn of $105.9M in Q2 2026 was higher than $76.4M in Q2 2025, despite lowered full-year guidance.
- All pipeline programs are early-stage (Phase 1/2) with high clinical failure risk; no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001601830-26-000097 |
| Document: 0001601830-26-000097-index-headers.html | 0001601830-26-000097 |
| Document: 0001601830-26-000097-index.html | 0001601830-26-000097 |
| Document: 0001601830-26-000097.txt | 0001601830-26-000097 |
| 8-K Data (Synthetic) | 0001601830-26-000097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $4.07 (−17.32%) |
Oct 15, 2026 12d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.07 (−2.28%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.07 (−2.28%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.07 (+2.28%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.07 (−2.28%) |
Oct 15, 2026 12d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.07 (+2.28%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.07 (−12.20%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.07 (−12.20%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $4.07 (+2.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $4.07 (+27.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers